Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24271468 | 0.81 | MEN1 (0.33) | SMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL24907384 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL29741097 | 0.65 | SMN1; SMN2 (0.32) | SMN1; SMN2MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL23284463 | 0.65 | SMN1; SMN2 (0.35) | SMN1; SMN2MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL25478021 | 0.64 | HSD17B10 (0.35) | SMN1; SMN2MEN1LMNAKMT2AHTT | |
| SCHEMBL30748231 | 0.60 | PDE2A (0.33) | SMN1; SMN2MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL30095779 | 0.60 | POLB (0.38) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21863548 | 0.60 | ALOX15 (0.50) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL23284452 | 0.59 | — | — | |
| SCHEMBL22435358 | 0.58 | TSHR (0.35) | MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | SMN1; SMN2 691/4885MEN1 3746/4885LMNA 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.